ncRNA name
hsa-miR-106a
Specific or universal ncRNAs
Universal ncRNAs
Class
MicroRNA
Biomarker
No
Biomarker application
Upstream regulatory factors
Not available
Downstream target
BCL10/caspase-7/ZEB1
Cancer name
Ovarian Cancer
Cancer site
Ovary
Treatment type
Chemotherapy
Drug
Paclitaxel
Impact of wild-type ncRNA on chemotherapy resistance
Down
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
Modulation of these microRNAs resensitizes PTX-resistant cancer cells by targeting BCL10, caspase-7, and ZEB1.
Tissue resource
ovarian serous tumours tissues
human ovarian carcinoma cell line SKOV3
human ovarian carcinoma paclitaxel-resistant sublines SKpac-8
human ovarian carcinoma paclitaxel-resistant sublines SKpac-10
human ovarian carcinoma paclitaxel-resistant sublines SKpac-11
human ovarian carcinoma paclitaxel-resistant sublines SKpac-12
human ovarian carcinoma paclitaxel-resistant sublines SKpac-16
human ovarian carcinoma paclitaxel-resistant sublines SKpac-17
ovarian serous tumours tissues
human ovarian carcinoma cell line SKOV3
human ovarian carcinoma paclitaxel-resistant sublines SKpac-8
human ovarian carcinoma paclitaxel-resistant sublines SKpac-10
human ovarian carcinoma paclitaxel-resistant sublines SKpac-11
human ovarian carcinoma paclitaxel-resistant sublines SKpac-12
human ovarian carcinoma paclitaxel-resistant sublines SKpac-16
human ovarian carcinoma paclitaxel-resistant sublines SKpac-17
Experiment
qRT-PCR,Western blot,Luciferase reporter assay
Institute
College of Medicine, CHA University
College of Medicine, CHA University
Country
South Korea
South Korea
Continent
Asia
Asia